Abstract:Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo, representing a viable therapeutic strategy for cancer treatment. Using phage display techniques, we previously identified a potent peptide activator of P53, termed PMI (TSFAEYWNLLSP), with binding affinities for both MDM2 and MDMX in the low nanomolar concentration range. Here we report an ultrahigh affinity, dual-specificity peptide antagonist of MDM2 and MDMX obtained through systematic mutational analysis and additivity-based molecular design. Functional assays of over 100 peptide analogs of PMI using surface plasmon resonance and fluorescence polarization techniques yielded a dodecameric peptide termed PMI-M3 (LTFLEYWAQLMQ) that bound to MDM2 and MDMX with Kd values in the low picomolar concentration range as verified by isothermal titration calorimetry. Co-crystal structures of MDM2 and of MDMX in complex with PMI-M3 were solved at 1.65 and 3.0 Å resolution, respectively. Similar to PMI, PMI-M3 occupied the P53-binding pocket of MDM2/MDMX, which was dominated energetically by intermolecular interactions involving Phe3, Tyr6, Trp7, and Leu10. Notable differences in binding between PMI-M3 and PMI were observed at other positions such as Leu4 and Met11 with MDM2, and Leu1 and Met11 with MDMX, collectively contributing to a significantly enhanced binding affinity of PMI-M3 for both proteins. By adding lysine residues to both ends of PMI and PMI-M3 to improve their cellular uptake, we obtained modified peptides termed PMI-2K (KTSFAEYWNLLSPK) and M3-2K (KLTFLEYWAQLMQK). Compared with PMI-2K, M3-2K exhibited significantly improved antitumor activities in vitro and in vivo in a P53-dependent manner. This super-strong peptide inhibitor of the P53-MDM2/MDMX interactions may become, in its own right, a powerful lead compound for anticancer drug development, and can aid molecular design of other classes of P53 activators as well for anticancer therapy.

Design, Synthesis, and Biological Evaluation of Lysine-Stapled Peptide Inhibitors of p53-MDM2/MDMX Interactions with Potent Antitumor Activity In Vivo

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Bicyclic Stapled Peptides Based on P53 As Dual Inhibitors for the Interactions of P53 with MDM2 and MDMX

Study on the design, synthesis, and activity of anti-tumor staple peptides targeting MDM2/MDMX

Synthesis and Biological Evaluation of Novel All-Hydrocarbon Cross-Linked Aza-Stapled Peptides.

D-Peptide Inhibitors of the P53-Mdm2 Interaction for Targeted Molecular Therapy of Malignant Neoplasms

Structural Basis for High-Affinity Peptide Inhibition of P53 Interactions with MDM2 and MDMX.

Systematic Mutational Analysis of Peptide Inhibition of the P53-Mdm2/Mdmx Interactions

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

A Dimethylbromobenzene-Cysteine Stapled Peptide Dual Inhibitor of the P53-Mdm2/mdmx Interactions

Small Molecule Inhibitors of the P53-Mdm2

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

D-Amino Acid Mutation of PMI As Potent Dual Peptide Inhibitors of P53-Mdm2/mdmx Interactions

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Α-Helix-mimicking Sulfono-γ-AApeptide Inhibitors for P53–mdm2/mdmx Protein–Protein Interactions

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors